Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): C. Royo-Cebrecos (1), I. Ambatlle (1), Ï. Robert-Montaner (2), J.M. Buldon (1), D. Vilanova (3), E. Bailles (1), E. Mahia (1), J. Pujadas (1), F. Cobo (1), S. Albiol (1)
Authors Affiliations(s): (1) Andorra Health Services, Andorra, (2) University of Nottingham, United Kingdom, (3) Genomictales, Andorra
Background:
Given cancer’s impact on society and vulnerability of patients to COVID-19, this study aims to describe demographics, diagnostic, treatment and outcomes of SARS-CoV-2 within a cancer patient cohort from Andorra. SARS-Cov2 serological response over time by means of a follow-up period of 6 and 12 months will further be assessed.
Methods:
Observational, unicentre, retrospective cohort study. All adult patients with cancer diagnosis within 5 years (2016-April 2020) were included since May 2020. During subsequent months, a comprehensive follow-up of these patients will be performed. Data was taken from medical records (HCIS, software SAAS) and inputted into a web form (https://forms.epidemixs.org/form/study/covoncoand).
Results:477 oncologic patients were included in the study, representing 0.62% of Andorra’s total population. Of these, 396 patients with complete data who underwent serological testing were analysed; 225 females (57%) with a mean age of 60.33 (IQ 51). At baseline, 350 (88.3%) patients had solid tumors and 49 (19%) presented metastatic diseases. Breast cancer was the main primary cancer site with 117 (29%) patients. 186 (47%) patients received active anti-cancer treatment, of which 89 (22%) received chemotherapy, 70 (18%) hormonal therapy, 68 (17%) biologics and 23 (5.8%) radiotherapy. Overall, 47 (11.9%) patients were seropositive (IgG or IgM positive) and 29 (7%) presented COVID-19 confirmed using rt-qPCR. No significant differences were observed between overall seroprevalence and anti-cancer treatments. Regarding COVID-19 diagnosis, only 38 (9%) patients were symptomatic, of which 24 (6%) reported a fever, 23 (6%) a cough and 23 (6%) general discomfort. Seventeen (41%) patients required hospital admission with 2 (12%) being admitted to ICU. November 2020 cutoff data showed that 13 patients with COVID-19 diagnosis (44%) died; 11 with advanced disease and 8 with palliative active treatment.
Conclusions:
This study includes most cancer patients with oncology follow-up care in Andorra. Solid tumors predominated over hematologic malignancies, breast cancer being the most common. Fever, cough and fatigue were symptoms most strongly associated with SARS-CoV-2 seropositivity. Seroprevalence proved similar to the general population at that time. Hospitalization rate was 40% and mortality was also elevated, predominantly within advanced cancer patients. Notable efforts should be placed on monitoring cancer populations in the upcoming months.
Keyword(s): Cancer Patients, Covid, serology
Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): C. Royo-Cebrecos (1), I. Ambatlle (1), Ï. Robert-Montaner (2), J.M. Buldon (1), D. Vilanova (3), E. Bailles (1), E. Mahia (1), J. Pujadas (1), F. Cobo (1), S. Albiol (1)
Authors Affiliations(s): (1) Andorra Health Services, Andorra, (2) University of Nottingham, United Kingdom, (3) Genomictales, Andorra
Background:
Given cancer’s impact on society and vulnerability of patients to COVID-19, this study aims to describe demographics, diagnostic, treatment and outcomes of SARS-CoV-2 within a cancer patient cohort from Andorra. SARS-Cov2 serological response over time by means of a follow-up period of 6 and 12 months will further be assessed.
Methods:
Observational, unicentre, retrospective cohort study. All adult patients with cancer diagnosis within 5 years (2016-April 2020) were included since May 2020. During subsequent months, a comprehensive follow-up of these patients will be performed. Data was taken from medical records (HCIS, software SAAS) and inputted into a web form (https://forms.epidemixs.org/form/study/covoncoand).
Results:477 oncologic patients were included in the study, representing 0.62% of Andorra’s total population. Of these, 396 patients with complete data who underwent serological testing were analysed; 225 females (57%) with a mean age of 60.33 (IQ 51). At baseline, 350 (88.3%) patients had solid tumors and 49 (19%) presented metastatic diseases. Breast cancer was the main primary cancer site with 117 (29%) patients. 186 (47%) patients received active anti-cancer treatment, of which 89 (22%) received chemotherapy, 70 (18%) hormonal therapy, 68 (17%) biologics and 23 (5.8%) radiotherapy. Overall, 47 (11.9%) patients were seropositive (IgG or IgM positive) and 29 (7%) presented COVID-19 confirmed using rt-qPCR. No significant differences were observed between overall seroprevalence and anti-cancer treatments. Regarding COVID-19 diagnosis, only 38 (9%) patients were symptomatic, of which 24 (6%) reported a fever, 23 (6%) a cough and 23 (6%) general discomfort. Seventeen (41%) patients required hospital admission with 2 (12%) being admitted to ICU. November 2020 cutoff data showed that 13 patients with COVID-19 diagnosis (44%) died; 11 with advanced disease and 8 with palliative active treatment.
Conclusions:
This study includes most cancer patients with oncology follow-up care in Andorra. Solid tumors predominated over hematologic malignancies, breast cancer being the most common. Fever, cough and fatigue were symptoms most strongly associated with SARS-CoV-2 seropositivity. Seroprevalence proved similar to the general population at that time. Hospitalization rate was 40% and mortality was also elevated, predominantly within advanced cancer patients. Notable efforts should be placed on monitoring cancer populations in the upcoming months.
Keyword(s): Cancer Patients, Covid, serology
Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): C. Royo-Cebrecos (1), I. Ambatlle (1), Ï. Robert-Montaner (2), J.M. Buldon (1), D. Vilanova (3), E. Bailles (1), E. Mahia (1), J. Pujadas (1), F. Cobo (1), S. Albiol (1)
Authors Affiliations(s): (1) Andorra Health Services, Andorra, (2) University of Nottingham, United Kingdom, (3) Genomictales, Andorra
Background:
Given cancer’s impact on society and vulnerability of patients to COVID-19, this study aims to describe demographics, diagnostic, treatment and outcomes of SARS-CoV-2 within a cancer patient cohort from Andorra. SARS-Cov2 serological response over time by means of a follow-up period of 6 and 12 months will further be assessed.
Methods:
Observational, unicentre, retrospective cohort study. All adult patients with cancer diagnosis within 5 years (2016-April 2020) were included since May 2020. During subsequent months, a comprehensive follow-up of these patients will be performed. Data was taken from medical records (HCIS, software SAAS) and inputted into a web form (https://forms.epidemixs.org/form/study/covoncoand).
Results:477 oncologic patients were included in the study, representing 0.62% of Andorra’s total population. Of these, 396 patients with complete data who underwent serological testing were analysed; 225 females (57%) with a mean age of 60.33 (IQ 51). At baseline, 350 (88.3%) patients had solid tumors and 49 (19%) presented metastatic diseases. Breast cancer was the main primary cancer site with 117 (29%) patients. 186 (47%) patients received active anti-cancer treatment, of which 89 (22%) received chemotherapy, 70 (18%) hormonal therapy, 68 (17%) biologics and 23 (5.8%) radiotherapy. Overall, 47 (11.9%) patients were seropositive (IgG or IgM positive) and 29 (7%) presented COVID-19 confirmed using rt-qPCR. No significant differences were observed between overall seroprevalence and anti-cancer treatments. Regarding COVID-19 diagnosis, only 38 (9%) patients were symptomatic, of which 24 (6%) reported a fever, 23 (6%) a cough and 23 (6%) general discomfort. Seventeen (41%) patients required hospital admission with 2 (12%) being admitted to ICU. November 2020 cutoff data showed that 13 patients with COVID-19 diagnosis (44%) died; 11 with advanced disease and 8 with palliative active treatment.
Conclusions:
This study includes most cancer patients with oncology follow-up care in Andorra. Solid tumors predominated over hematologic malignancies, breast cancer being the most common. Fever, cough and fatigue were symptoms most strongly associated with SARS-CoV-2 seropositivity. Seroprevalence proved similar to the general population at that time. Hospitalization rate was 40% and mortality was also elevated, predominantly within advanced cancer patients. Notable efforts should be placed on monitoring cancer populations in the upcoming months.
Keyword(s): Cancer Patients, Covid, serology
Session Type: 1,5-hour Oral Session
Session Title: 1,5-hour Oral Session
Authors(s): C. Royo-Cebrecos (1), I. Ambatlle (1), Ï. Robert-Montaner (2), J.M. Buldon (1), D. Vilanova (3), E. Bailles (1), E. Mahia (1), J. Pujadas (1), F. Cobo (1), S. Albiol (1)
Authors Affiliations(s): (1) Andorra Health Services, Andorra, (2) University of Nottingham, United Kingdom, (3) Genomictales, Andorra
Background:
Given cancer’s impact on society and vulnerability of patients to COVID-19, this study aims to describe demographics, diagnostic, treatment and outcomes of SARS-CoV-2 within a cancer patient cohort from Andorra. SARS-Cov2 serological response over time by means of a follow-up period of 6 and 12 months will further be assessed.
Methods:
Observational, unicentre, retrospective cohort study. All adult patients with cancer diagnosis within 5 years (2016-April 2020) were included since May 2020. During subsequent months, a comprehensive follow-up of these patients will be performed. Data was taken from medical records (HCIS, software SAAS) and inputted into a web form (https://forms.epidemixs.org/form/study/covoncoand).
Results:477 oncologic patients were included in the study, representing 0.62% of Andorra’s total population. Of these, 396 patients with complete data who underwent serological testing were analysed; 225 females (57%) with a mean age of 60.33 (IQ 51). At baseline, 350 (88.3%) patients had solid tumors and 49 (19%) presented metastatic diseases. Breast cancer was the main primary cancer site with 117 (29%) patients. 186 (47%) patients received active anti-cancer treatment, of which 89 (22%) received chemotherapy, 70 (18%) hormonal therapy, 68 (17%) biologics and 23 (5.8%) radiotherapy. Overall, 47 (11.9%) patients were seropositive (IgG or IgM positive) and 29 (7%) presented COVID-19 confirmed using rt-qPCR. No significant differences were observed between overall seroprevalence and anti-cancer treatments. Regarding COVID-19 diagnosis, only 38 (9%) patients were symptomatic, of which 24 (6%) reported a fever, 23 (6%) a cough and 23 (6%) general discomfort. Seventeen (41%) patients required hospital admission with 2 (12%) being admitted to ICU. November 2020 cutoff data showed that 13 patients with COVID-19 diagnosis (44%) died; 11 with advanced disease and 8 with palliative active treatment.
Conclusions:
This study includes most cancer patients with oncology follow-up care in Andorra. Solid tumors predominated over hematologic malignancies, breast cancer being the most common. Fever, cough and fatigue were symptoms most strongly associated with SARS-CoV-2 seropositivity. Seroprevalence proved similar to the general population at that time. Hospitalization rate was 40% and mortality was also elevated, predominantly within advanced cancer patients. Notable efforts should be placed on monitoring cancer populations in the upcoming months.
Keyword(s): Cancer Patients, Covid, serology